Clinical Trials

NCT Number: NCT03067051 Phase: Phase 1|Phase 2 Trial Summary: The rationale for the study is to obtain safety and efficacy data as well as to establish dose parameters for the SpectraCure P18 System with IDOSE®, with verteporfin for injection – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): SpectraCure AB Acronym:

NCT Number: NCT03232164 Phase: Early Phase 1 Trial Summary: The overall goal of this research is to validate and develop a non-invasive imaging biomarker of prostate cancer detection, progression, and recurrence. Development of such a bioma – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Wisconsin, Madison Acronym:

NCT Number: NCT02861573 Phase: Phase 1|Phase 2 Trial Summary: The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer ( – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Merck Sharp & Dohme LLC Acronym:

NCT Number: NCT02717156 Phase: Phase 2 Trial Summary: This is a multi-cohort single arm phase II/screening trial of the combination of a fusion protein that binds EphrinB2 and blocks interaction with cell surface EphB receptors (sEphB – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Southern California|National Cancer Institute (NCI) Acronym:

NCT Number: NCT02769962 Phase: Phase 1|Phase 2 Trial Summary: Background: EP0057 consists of a sugar molecule cyclodextrin linked to a chemotherapy drug called camptothecin. The combined molecule or “nanoparticle drug conjugate” travels throu – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Acronym:

NCT Number: NCT02484404 Phase: Phase 1|Phase 2 Trial Summary: Durvalumab is a drug that may help people s immune systems respond to and kill cancer cells. Olaparib is a drug that may inhibit repairing DNA damage of cancer cells. Cediranib is – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): National Cancer Institute (NCI)|National […]

NCT Number: NCT02334579 Phase: Not Applicable Trial Summary: The purpose of this study is to find out the effects (good and bad) of highly focused radiation on you and your prostate cancer. The purpose of this evaluation is to see if this tr – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Swedish Medical […]

NCT Number: NCT02600156 Phase: Not Applicable Trial Summary: The primary purpose of this study is to evaluate the feasibility and safety of MRI-guided focal laser ablation (Laser-Induced Interstitial Thermal Therapy, LITT) to treat low-risk – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Mayo Clinic Acronym:

NCT Number: NCT02307058 Phase: Not Applicable Trial Summary: The purpose of this research study is to learn about: 1) improving control of prostate cancer using an extra high dose radiation treatment to the MRI defined high risk tumor areas, – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Miami Acronym: BLaStM

NCT Number: NCT02526368 Phase: EARLY PHASE1 Trial Summary: This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon C13 pyruvate works in finding prostate cancer that exhibits po – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of California, San Francisco Acronym: pyruvate